Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
August 24, 2007

Gene Logic Tasked with Repositioning Merck Serono Drugs

  • Gene Logic plans to research alternative development paths for several Merck Serono clinical candidates under a drug-repositioning agreement. All the candidates were discontinued or de-prioritized for reasons other than safety, according to the companies.

    Gene Logic will receive success-based milestones and royalties. If Gene Logic identifies a new therapeutic use for any compound, the company has the right to exclusively license the drug so long as Merck Serono opts out of development. Merck Serono then would be entitled to success-based milestone and royalty payments on these licensed candidates.

    Gene Logic has similar repositioning collaborations with Eli Lilly, Lundbeck, Abbott, Organon, Roche, and Pfizer.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.